Abstract:Flow chart of patient enrollment and table of EGFR exon 19 deletion (ex19del) variants, with Kaplan–Meier curve for progression free survival (PFS) and overall survival (OS) of first‐line tyrosine kinase inhibitor (TKI) treatment and incidence of secondary T790M mutation, in EGFR ex19del mutations subgroups. (A, B) Comparison of PFS and OS between the classic and nonclassic EGFR ex19del group; (C) PFS in the EGFR ex19del subgroup with deletion starting at E746 accompanying insertion mutation (E746/ins+), comparing with the patients with other ex19del variants; (D, E), comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) tyrosine kinase inhibitor (TKI) in patients with classic EGFR ex19del group; (F, G) comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) TKI in patients with nonclassic EGFR ex19del group; (H) incidence of secondary T790M after resistant to first or second generation TKIs, in each subgroup of EGFR ex19del, and comparison between the classic and nonclassic EGFR ex19del groups, between EGFR ex19del subgroups starting at E746 and at other site (ex19del/E746+ vs. ex19del/other site), between EGFR ex19del subgroups with and without insertion mutations (EGFR ex19del/ins+ vs. EGFR ex19del/ins−), and between EGFR ex19del subgroups with deletion length of 15 nucleotides or of other deletion length (ex19del/15+ vs. ex19del/other length). Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018–June 2022) and correlated them with median progression‐free survival (mPFS) and median overall survival (mOS). Results We identified 17 different EGFR ex19del variants in 101 patients. Between the classic (E746_A750del, 64.4%) and nonclassic groups (the rest variants), no significant difference was observed in mPFS (13.5 vs. 19.3 months, p = 0.18) or mOS (44.1 vs. 77.0 months, p = 0.06). mPFS showed no significant difference between ex19del subgroups classified based on the presence of insertion (ex19delins), starting position or length of deletion. However, patients with ex19delins starting at E746 showed longer mPFS than the others (29.7 vs. 12.5 months, p = 0.04), and patients with ex19del of 15 nucleotides had shorter mOS than the others (44.1 vs. 77.0 months, p = 0.03). In multivariate analysis, ex19delins independently predicted a better PFS (HR = 0.311, p = 0.03); however, 15 nucleotide deletion was no longer associated with OS (HR = 0.181, p = 0.11). Secondary T790M mutation incidence was significantly higher in the ex19del subgroup starting at E746 than the others (64.7% vs. 30.8%, p = 0.04). Conclusions Our study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first‐line therapy.

Exon 19 Deletion Association with Progression-Free Survival Compared to L858r Mutation at Exon 21 in Treatment with First-Line Egfr-Tkis: A Meta-Analysis of Subgroup Data from Eight Phase Iii Randomized Controlled Trials.

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Different Stories for Different EGFR Exon 19 Deletion Variants

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Different Efficacy of EGFR Tyrosine Kinase Inhibitors and Prognosis in Patients with Subtypes of EGFR-mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis.

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

[Clinical characteristics and outcomes of lung cancer patients  with EGFR mutations in exons 19 and 21].

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.

Comparison of Therapeutic Effects of EGFR-tyrosine Kinase Inhibitors on 19del and L858R Mutations in Advanced Lung Adenocarcinoma and Effect on Cellular Immune Function